Rep. Norm Thurston — Voting Record

Bill

Number

H.B. 25 (2018GS)

Sponsor

Rep. Daw, B.

Final action

Governor Signed 3/16/2018

Outcome

Became law — signed by Gov. Gary R. Herbert

Summary

What it does

• This bill:
• amends the required composition of the Cannabinoid Product Board; and
• amends the duties of the Cannabinoid Product Board to include review of expanded cannabinoid products.

Every vote on this bill

Bill text

CANNABINOID PRODUCT BOARD MEMBERSHIP
AMENDMENTS
GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Brad M. Daw
Senate Sponsor: 
 Evan J. Vickers
LONG TITLE
Committee Note:
The Health and Human Services Interim Committee recommended this bill.
General Description:
This bill amends provisions related to the Cannabinoid Product Board.
Highlighted Provisions:
This bill:
▸ amends the required composition of the Cannabinoid Product Board; and
▸ amends the duties of the Cannabinoid Product Board to include review of expanded
cannabinoid products.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
26-61-201
, as enacted by Laws of Utah 2017, Chapter 398
26-61-202
, as enacted by Laws of Utah 2017, Chapter 398
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
26-61-201
 is amended to read:
26-61-201.
Cannabinoid Product Board.
(1) There is created the Cannabinoid Product Board within the department.
(2) The department shall appoint, in consultation with a professional association based
in the state that represents physicians, seven members to the Cannabinoid Product Board as
follows:
(a) three individuals who are medical research professionals; and
(b) four physicians.
(3) The department shall [
appoint board members under Subsection (2) such
] 
ensure
that [
three
] 
at least one
 of the board members [
are members
] 
appointed under Subsection (2) is
a member
 of the Controlled Substances Advisory Committee created in Section 
58-38a-201
.
(4) (a) Four of the board members appointed under Subsection (2) shall serve an initial
term of two years and three of the board members appointed under Subsection (2) shall serve
an initial term of four years.
(b) Successor board members shall each serve a term of four years.
(5) The department may remove a board member without cause.
(6) The board shall nominate a board member to serve as chairperson of the board by a
majority vote of the board members.
(7) The board shall meet as often as necessary to accomplish the duties assigned to the
board under this chapter.
(8) Each board member, including the chair, has one vote.
(9) (a) A majority of board members constitutes a quorum.
(b) A vote of a majority of the quorum at any board meeting is necessary to take action
on behalf of the board.
(10) A board member may not receive compensation for the member's service on the
board, but may, in accordance with rules adopted by the board in accordance with Title 63G,
Chapter 3, Utah Administrative Rulemaking Act, receive:
(a) per diem at the rate established under Section 
63A-3-106
; and
(b) travel expenses at the rate established under Section 
63A-3-107
.
Section 2. Section 
26-61-202
 is amended to read:
26-61-202.
Cannabinoid Product Board -- Duties.
(1) The board shall review any available research related to the human use of a
cannabinoid product 
or an expanded cannabinoid product
 that:
(a) was conducted under a study approved by an IRB; or
(b) was conducted or approved by the federal government.
(2) Based on the research described in Subsection (1), the board shall evaluate the
safety
, risks,
 and efficacy of cannabinoid products 
and expanded cannabinoid products
,
including:
(a) medical conditions that respond to cannabinoid products 
and expanded cannabinoid
products
;
(b) cannabinoid dosage amounts and medical dosage forms; and
(c) interaction of cannabinoid products 
and expanded cannabinoid products
 with other
treatments.
(3) Based on the board's evaluation under Subsection (2), the board shall develop
guidelines for a physician recommending treatment with a cannabinoid product 
or an expanded
cannabinoid product
 that includes a list of medical conditions, if any, that the board determines
are appropriate for treatment with a cannabinoid product 
or an expanded cannabinoid product
.
(4) The board shall submit the guidelines described in Subsection (3) to:
(a) the director of the Division of Occupational and Professional Licensing; and
(b) the Health and Human Services Interim Committee.
(5) The board shall report the board's findings before November 1 of each year to the
Health and Human Services Interim Committee.
Legislative Review Note
Office of Legislative Research and General Counsel